IRMD — IRadimed Corporation

IRadimed Corporation Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $20.5 million, a slight increase of 0.5% from $20.4 million in Q2 2025.
• GAAP Earnings Per Share (EPS): $0.41, down from $0.45 year-over-year.
• Non-GAAP EPS: $0.46, compared to $0.49 in Q2 2025.
• Gross Margin: 74%, down from 78% in the previous year, attributed to higher manufacturing costs during the ramp-up of the new 3870 pump.
• Net Income: $5.2 million, compared to $5.8 million in Q2 2025.
• Cash and Cash Equivalents: $59.1 million, up from $51.2 million at year-end.
• Operating Expenses: $8.8 million, down 4% from $9.2 million, with a notable decrease in general and administrative expenses.

2. Strategic Updates and Business Highlights:

• Successfully launched the 3870 MR IV pump system, achieving production of over 130 units in Q2.
• Strong customer acceptance led to bookings more than double the units shipped, indicating robust demand.
• The transition from the older 3860 pump systems to the new 3870 is expected to drive significant growth, particularly from the replacement of aging units.
• The company is also seeing growth in MRI compatible patient monitoring systems and disposables, with a 12% and 14% year-over-year increase in revenue, respectively.
• The introduction of the quad pump system is anticipated to enhance revenue per site due to increased utilization.

3. Forward Guidance and Outlook:

• For Q3 2026, IRadimed expects revenue between $23 million and $24.5 million, with GAAP EPS projected at $0.49 to $0.54 and non-GAAP EPS at $0.54 to $0.59.
• Full-year revenue guidance remains at $91 million to $96 million, with GAAP EPS of $1.90 to $2.05 and non-GAAP EPS of $2.09 to $2.24.
• The company anticipates improved gross margins in the second half of the year as production efficiencies are realized.

4. Challenges and Points of Concern:

• The gross margin decline reflects increased costs associated with the initial production ramp of the 3870 pump, which may pose short-term profitability challenges.
• The effective tax rate has increased to 24.2%, which could impact net income if it remains elevated.
• There is a risk of operational inefficiencies as the company scales production, although management is confident in overcoming these through experience and learning curves.

5. Notable Q&A Insights:

• Management clarified that no additional staffing is required for the ramp-up; efficiencies will come from the existing workforce's experience.
• The transition from the 3860 to 3870 systems is expected to maintain or enhance service and disposable revenue, with the quad system driving higher utilization.
• Lead times for new orders are expected to remain competitive, with a potential return to historic levels of 4-6 months as demand stabilizes.

Overall, IRadimed is positioned for growth with strong demand for its new products, although it faces challenges related to production costs and operational scaling.